Sanofi Pasteur said that the contract supported by the HHS Biomedical Advanced Research and Development Authority (BARDA) affords rapid response and production of a strain-matched pandemic influenza vaccine in the event of a declared pandemic.
The contract covers the year-round availability of sufficient eggs and other essential supplies to support production of interpandemic or pandemic influenza vaccine at the company’s full production capacity.
The year-round supply also enables Sanofi Pasteur to collaborate with the US government to develop vaccines against other potential pandemic virus strains as they are identified.
Sanofi Pasteur president and CEO Wayne Pisano said that this three-year contract demonstrates that egg-based technology remains a cornerstone of pandemic planning and preparedness.
"We welcome opportunities to discuss similar flock preservation initiatives with government health authorities around the world," Pisano said.